Skip to Content

Tranzyme Pharma to Present at American Chemical Society (ACS) 2009 National Meeting

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Aug 14, 2009 - Tranzyme Pharma, a late stage biopharmaceutical company engaged in the discovery and development of first-in-class small molecule therapeutics, announced today that Mark L. Peterson, PhD., Tranzyme's Vice President of Intellectual Property and Operations Tranzyme, will present at the upcoming 2009 ACS National Meeting being held August 16-20, 2009 in Washington, DC.

Dr. Peterson's invited presentation “From Macrocyclic Libraries to the Clinic” will take place on Monday, August 17th at 4:15pm EDT in the Walter E. Washington Convention Center, Ballroom C as part of a special symposium session on Macrocyclization as a Tool in Drug Design organized by the ACS Division of Medicinal Chemistry.

Originating from its proprietary library of conformationally-defined macrocyclic compounds, Tranzyme's internal R&D efforts discovered a potent and selective ghrelin agonist, TZP-101. The ghrelin receptor has emerged recently as a novel therapeutic target for gastrointestinal (GI) motility disorders, an area poorly served by current pharmaceutical products. TZP-101 now has completed Phase 2 clinical studies for the treatment of postoperative ileus (POI) and acute gastroparesis. Dr. Peterson will present an overview of these discovery efforts, including a detailed SAR discussion, as well as summarize the preclinical and clinical results with the compound.

Tranzyme is also pursuing development of several other macrocyclic compounds emanating from its internal research program, including a second generation, oral ghrelin agonist, TZP-102, currently in Phase 2 trials, and two preclinical compounds, TZP-201 for severe diarrhea indications such as chemotherapy-induced diarrhea, and TZP-301, a ghrelin antagonist, for metabolic disorders.

For more information on Tranzyme, please visit:




Contact: Tranzyme Pharma
Vipin K. Garg, PhD, 919-313-4764
President and CEO
Mark L. Peterson, PhD, 819-820-6845
VP, IP & Operations
Susan S. Josselyn, 919-313-4761
Corporate Communications Mgr


Posted: August 2009